Biocon Share News - Latest Updates, Live News & More

More news about Biocon

Biocon Limited Submits Employee Welfare Trust Amendment Deed with Trustee Changes

Biocon Limited has submitted Amendment #7 to its Employee Welfare Trust deed, executed on March 27, 2026, involving changes to the Trust's Board of Trustees. Mr. Krishnachar Nandakumar and Ms. Maninder Kapoor Puri will resign as trustees effective March 31, 2026, and will be replaced by Mr. Mukesh Kamath and Mr. Naveen Narayanan from April 01, 2026. The amendment modifies Article 8 of the trust deed and has been submitted to stock exchanges in compliance with SEBI regulations.

27Mar 26

Biocon Limited Appoints Shreehas Tambe as CEO in Major Leadership Transition

Biocon Limited announced major leadership changes with Shreehas Tambe appointed as CEO & Managing Director and Kedar Upadhye as CFO, effective April 1, 2026. This transition supports the integration of Biocon Biologics as a wholly owned subsidiary, creating a unified corporate structure. Under Tambe's leadership at Biocon Biologics, the company achieved USD 5.50 billion valuation and became a Top 5 global biosimilar company by revenue.

13Mar 26

Biocon Arm Biocon Pharma Limited Wins U.S. FDA Approval For Liraglutide Injection

Biocon Limited announced that its wholly-owned subsidiary Biocon Pharma Limited has received U.S. FDA approval for Liraglutide Injection (gVictoza®) ANDA, designed for Type 2 diabetes treatment in adults, adolescents and children aged 10 years and above. This marks the company's second Liraglutide-based product approval in recent weeks, following the earlier gSaxenda® approval, significantly strengthening Biocon's complex drug portfolio and positioning in the U.S. diabetes treatment market.

12Mar 26

Biocon Reports 9.2% Revenue Growth in Q3FY26 with Strong Profitability Recovery

Biocon Limited reported strong Q3FY26 results with consolidated revenue growing 9.2% YoY to ₹41,730 million. Net profit attributable to shareholders surged to ₹1,438 million from ₹251 million, while basic EPS improved significantly to ₹1.08. Nine-month revenue reached ₹1,24,104 million with net profit of ₹2,597 million, reflecting the company's operational strength and market expansion.

09Mar 26

FDA Reduces Regulatory Requirements for Biosimilar Drug Manufacturers

The FDA has reduced regulatory requirements for companies developing biosimilar versions of expensive biologic drugs. This policy change aims to streamline the approval process for cheaper alternatives to costly biologic medications. The development could benefit pharmaceutical companies like Biocon that specialize in biosimilar drug development and manufacturing.

05Mar 26

Biocon Limited to Participate in JP Morgan's Annual India Credit Investor Trip on March 11, 2026

Biocon Limited has announced its participation in JP Morgan's annual flagship India Credit Investor Trip on March 11, 2026, through a virtual group interaction format. The company informed stock exchanges under Regulation 30(6) of SEBI Listing Regulations and confirmed that no Unpublished Price Sensitive Information will be disclosed during the meeting. The event details will be available on the company's website, and the schedule remains subject to change due to potential exigencies.

04Mar 26

Biocon Invests ₹315 Crore in Biocon Biosphere and Biocon Pharma Using OCRPS

Biocon Limited has completed a ₹315 crore investment in its wholly owned subsidiaries Biocon Biosphere Limited and Biocon Pharma Limited through Optionally Convertible Redeemable Preference Shares. The investment aims to support ongoing business operations, working capital needs, and general corporate purposes while maintaining full ownership of both pharmaceutical manufacturing entities.

25Feb 26

Biocon Secures U.S. FDA Approval For Weight Loss Drug Liraglutide With $127M Market

Biocon Limited has secured U.S. FDA approval for its Liraglutide Injection (gSaxenda®) for chronic weight management, marking a significant regulatory milestone. The GLP-1 therapy targets a US $127 million market opportunity and represents validation of Biocon's complex formulation capabilities in the fast-growing weight management therapeutic segment.

13Feb 26

Biocon Shares Q3FY26 Earnings Call Recording Link Under Regulation 30

Biocon Limited has made available the audio and video recordings of its Q3FY26 earnings call conducted on February 13, 2026, in compliance with SEBI Regulation 30. The company reported mixed Q3FY26 results with revenue growth of 10.4% to ₹6,213M but posted a standalone net loss of ₹764M due to exceptional items worth ₹1,963M.

07Feb 26

Fitch Ratings Upgrades Biocon Biologics Outlook to Positive, Affirms BB- Rating

Fitch Ratings has revised Biocon Biologics' outlook to positive while maintaining its BB- rating, citing expectations of sustained financial leverage reduction. The company, serving over 6.3 million patients across 120+ countries with 10 commercialized biosimilars, also received affirmation of its BB rating on USD 800 million secured notes.

30Jan 26

Biocon Limited Completes Rs. 2,000 Crore Commercial Paper Buyback

Biocon Limited successfully completed the buyback of commercial papers totaling Rs. 2,000.00 crore on January 30, 2026, comprising two separate issues under ISINs INE376G14040 (Rs. 1,800.00 crore) and INE376G14057 (Rs. 200.00 crore). The company fulfilled all regulatory requirements under SEBI Master Circular and confirmed adherence to FIMMDA guidelines.

28Jan 26

Biocon Limited Receives VAI Status from US FDA for API Facility Inspection

Biocon Limited has received a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration for its API facility in Andhra Pradesh. The status follows an inspection conducted between November 3rd and 7th, 2025. The company has notified both BSE and NSE about this regulatory development as per Regulation 30 compliance requirements.

28Jan 26

S&P Global Upgrades Biocon Biologics Credit Rating to 'BB+' with Stable Outlook

S&P Global Ratings upgraded Biocon Biologics' credit rating to 'BB+' from 'BB' with stable outlook following successful capital restructuring. The upgrade reflects simplified capital structure through US$460 million equity issuance to settle US$1 billion CCPS with Viatris Inc. S&P projects significant debt reduction from INR248 billion to INR115 billion and FFO-to-debt ratio improvement to 22% by fiscal 2026, reaching 30% by fiscal 2027. The stable outlook is supported by expected revenue growth of 15% in biosimilars business and new product launches including Denosumab.

20Jan 26

SBI Mutual Fund Increases Biocon Stake to 7.04% Through Strategic Share Acquisition

SBI Mutual Fund has substantially increased its stake in Biocon Ltd to 7.0379% from 5.3445% by acquiring 3.35 crore shares on January 16, 2026. The acquisition, executed through qualified institutional placement and market purchases, triggered mandatory SEBI disclosure requirements due to the 2% shareholding increase. This strategic investment demonstrates institutional confidence in the biotechnology company's prospects.

15Jan 26

Biocon Completes ₹4,150 Crore QIP with Major Allocation to SBI, ICICI Funds

Biocon successfully raised ₹4,150 crores through QIP, issuing 112.66 crore shares at ₹368.35 each. Major allocation went to SBI and ICICI Prudential MF with 29.51% each. The funds will primarily support the acquisition of remaining Biocon Biologics shares from Mylan Inc., making it a wholly-owned subsidiary.

15Jan 26

Biocon Completes ₹41,500 Crore QIP Issue with Allotment of 11.27 Crore Equity Shares

Biocon Limited successfully completed its QIP issue on January 14, 2026, allotting 11,26,64,585 equity shares at ₹368.35 per share to raise ₹41,500 million. The issue saw strong participation from major mutual fund houses including SBI, ICICI Prudential, and Mirae Asset funds. The capital raise increased Biocon's paid-up share capital to ₹8,10,45,38,865 with total equity shares reaching 1,62,09,07,773.

14Jan 26

Biocon Limited Fund Raising Committee Approves Placement Document for Qualified Institutions Placement

Biocon Limited's Fund Raising Committee approved the Placement Document for its Qualified Institutions Placement on January 14, 2026, during a meeting held from 10:12 p.m. to 10:20 p.m. The QIP involves equity shares with ₹5 face value and complies with SEBI ICDR Regulations and Companies Act provisions. The company has informed BSE and NSE about this development as part of regulatory compliance under Regulation 30.

14Jan 26

Biocon Completes ₹4,151 Crore QIP with Allotment of 11.27 Crore Shares at ₹368.35 Each

Biocon Limited successfully completed its Qualified Institutions Placement on January 14, 2026, allotting 11,26,64,585 equity shares at ₹368.35 per share to qualified institutional buyers. The issue price represented a 5.00% discount to the floor price of ₹387.74, raising approximately ₹4,151 crores for the pharmaceutical company. The QIP opened on January 12, 2026 and closed within two days, demonstrating strong institutional investor interest and efficient execution under SEBI regulations.

13Jan 26

Biocon Limited Schedules Board Meeting and Earnings Conference Call for Q3FY26 Results

Biocon Limited has scheduled its Board of Directors meeting for February 12, 2026 to approve Q3FY26 financial results for the quarter and nine months ended December 31, 2025. The company will conduct an earnings conference call for analysts and investors on February 13, 2026 at 09:00 hrs IST via Zoom platform. Trading window for the company's securities remains closed from January 1-14, 2026, reopening on February 15, 2026.

13Jan 26

Biocon QIP to ease balance sheet pressure; metals, PSU banks favoured in near term: Nischal Maheshwari

Market expert Nischal Maheshwari views Biocon's equity raise positively despite ₹5,000 crore debt concerns, expecting strong cash flows to manage debt over 2-3 years while QIP funds BBL stake buyout. He favours PSU banks for short-term gains and private banks for medium-term investment, while highlighting opportunities in metals and power sector EPC players following recent corrections.

12Jan 26

Biocon Opens ₹4,500-Crore QIP To Fund Biologics Integration

Biocon Ltd. launched a ₹4,500 crore QIP at ₹387.74 floor price to fund the integration of Biocon Biologics, with ₹3,620 crore allocated for Mylan's $815 million stake acquisition. The deal combines $400 million cash payment and $415 million share swap, targeting completion by March 2026 to create a unified global biopharma leader in diabetes, oncology, and immunology markets.

12Jan 26

Biocon Launches ₹4,500 Crore QIP Following Board and Shareholder Approvals

Biocon has launched its Qualified Institutional Placement on January 12, 2026, targeting ₹4,500.00 crores in capital raising. The pharmaceutical company obtained necessary board and shareholder approvals last month before initiating this significant institutional fundraising exercise. The QIP provides Biocon access to qualified institutional investors for strengthening its capital base.

12Jan 26

Biocon launches ₹4,150-crore QIP with floor price set at ₹387.74 per share

Biocon Limited has launched a ₹4,150-crore QIP with a floor price of ₹387.74 per share, approved by the board on 6 December 2025 and opened on 12 January 2026. The company may offer up to 5% discount per SEBI regulations, with an indicative issue price of ₹368.35. Stock closed at ₹370.90 on 12 January 2026, down 2.29%, trading below the floor price. Recent developments include subsidiary's plans for three new oncology biosimilars and a licensing agreement with Ajanta Pharma for semaglutide marketing across 26 countries.

12Jan 26

Biocon Sets Floor Price at ₹387.74 Per Share for Equity Transaction

Biocon has set a floor price of ₹387.74 per share for its equity transaction, establishing a minimum valuation threshold. This mechanism provides price protection and demonstrates the company's commitment to maintaining appropriate share valuations during the offering process.

12Jan 26

Biocon Limited Opens Qualified Institutions Placement at ₹387.74 Floor Price Per Share

Biocon Limited has launched its Qualified Institutions Placement with a floor price of ₹387.74 per equity share, following approvals from the Board of Directors on December 06, 2025, and shareholders on December 31, 2025. The Fund Raising Committee authorized the QIP opening on January 12, 2026, with the flexibility to offer up to 5% discount on the floor price. The final issue price will be determined in consultation with book running lead managers, while trading window restrictions remain in place for compliance with insider trading regulations.

12Jan 26

Biocon Receives USFDA Approval for Everolimus Tablets in Multiple Strengths

Biocon has obtained USFDA approval for Everolimus tablets in 2mg, 3mg, and 5mg strengths for treating Tuberous Sclerosis Complex and SEGAs. This regulatory milestone expands Biocon's oncology portfolio in the US market and provides healthcare providers with flexible dosing options for rare neurological conditions.

12Jan 26

Biocon Subsidiary Receives U.S. FDA Approval for Everolimus Tablets in Multiple Strengths

Biocon Limited's subsidiary Biocon Pharma Limited has received U.S. FDA approval for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths. The medication is indicated for treating adult and pediatric patients with Tuberous Sclerosis Complex conditions, including SEGA and TSC-associated seizures. The approval strengthens Biocon's vertically integrated drug product portfolio.

08Jan 26

Biocon Executive Chairperson Criticizes Andhra Pradesh's 75% Local Employment Mandate

Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Ltd, has criticized the Andhra Pradesh Employment of Local Candidates in Industries/Factories Act, which reserves 75% of private sector jobs for eligible locals. The Act, enacted in 2019 and enforced since October 2019, has sparked debate between advocates of skill-based hiring and supporters of regional employment security. Mazumdar-Shaw argues that such mandates are detrimental to businesses, while critics contend that local job reservations are justified given government incentives provided to companies.

06Jan 26

Biocon Biologics Unveils Three Major Oncology Biosimilars at J.P. Morgan Conference

Biocon Biologics announced three major oncology biosimilars including Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab at the J.P. Morgan Healthcare Conference, representing substantial market opportunities totaling over $75 billion. The company outlined strategic integration plans as a wholly owned subsidiary of Biocon Limited, expected to complete by March 31, 2026, while Biocon shares closed down 1.21% at ₹386.60.

06Jan 26

Biocon Completes BBL Acquisition as Mylan Files SEBI Disclosure for 6.10% Stake

Biocon Limited successfully completed its strategic acquisition of Biocon Biologics Limited, acquiring 33.38 crore BBL shares and allotting 17.13 crore equity shares to investors including Mylan Inc., which received 9.20 crore shares representing 6.10% stake and filed mandatory SEBI disclosure.

02Jan 26

Biocon Issues ₹2,000 Crore Commercial Papers for Short-Term Funding

Biocon has issued commercial papers worth ₹2,000 crores as part of its short-term funding strategy. Commercial papers are unsecured debt instruments used by companies to meet immediate working capital and operational requirements, providing financial flexibility for business operations.

02Jan 26

Biocon Limited Issues ₹200 Crore Commercial Papers on Private Placement Basis

Biocon Limited has issued Commercial Papers worth ₹200 crores on private placement basis with 6.80% interest rate and 60-day tenure. The papers, allotted on January 2, 2026, will mature on March 3, 2026, and are proposed for listing on NSE. The entire issue has been allocated to Kotak Mahindra funds with IND A1+ credit rating and no security created over company assets.

24Dec 25

Biocon Declares Record Date for ₹1,800 Crore Commercial Paper Maturity

Biocon Limited has declared March 19, 2026 as the record date for its ₹1,800 crore commercial paper maturity, one day before the March 20, 2026 maturity date. The commercial paper, with ISIN INE376G14040, carries a 6.85% coupon rate and was issued on December 22, 2025, with allotment to prominent mutual fund houses including SBI, Axis, and Aditya Birla Sun Life liquid funds.

23Dec 25

Biocon Partners With Ajanta Pharma to Market Semaglutide Across 26 International Markets

Biocon has formed a strategic partnership with Ajanta Pharma to market semaglutide, a diabetes treatment medication, across 26 international markets. This collaboration aims to expand Biocon's diabetes treatment portfolio globally, leveraging combined expertise and distribution networks to reach patients in multiple countries.

23Dec 25

Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab from FKB

Biocon Biologics has announced securing full and exclusive global rights for biosimilar adalimumab (Hulio) from FKB, superseding their previous commercialization-only agreement. The enhanced deal grants end-to-end control over manufacturing, commercialization, and development activities, with FKB participating in development costs while receiving technology license fees and royalties. Commercial production will begin following technology transfer and regulatory approvals, strengthening Biocon's position in the global immunology biosimilars market.

19Dec 25

Biocon Receives EIR With VAI Status From U.S. FDA For New Jersey Facility

Biocon has received an EIR with VAI status from the U.S. FDA for its Cranbury, New Jersey facility following an October cGMP inspection. The VAI classification indicates that while the FDA identified areas for improvement, these observations do not require immediate regulatory enforcement action, allowing Biocon to address them through voluntary corrective measures.

17Dec 25

Biocon Biologics Named Asia IP Elite 2025 by IAM for Ninth Consecutive Year

Biocon Biologics Limited has been named an Asia IP Elite for 2025 by Intellectual Asset Management (IAM), marking the ninth consecutive year for Biocon entities. The award, presented at IPBC Asia in Tokyo, recognizes exceptional IP value creation. Biocon Biologics, serving over 6.30 million patients across 120 countries, has commercialized 10 biosimilars and maintains a pipeline of 20 biosimilar assets. CEO Shreehas Tambe emphasized the company's commitment to innovation and expanding access to affordable therapies globally.

16Dec 25

Biocon Gets Credit Rating Reaffirmation from CRISIL

Biocon Limited has received a credit rating reaffirmation from CRISIL Ratings Limited for its bank loan facilities of ₹250.00 crores. CRISIL has maintained Biocon's long-term rating at CRISIL AA/Stable and short-term rating at CRISIL A1+. The reaffirmation indicates high safety for timely servicing of financial obligations and the highest degree of safety for short-term debt obligations. This information was disclosed to stock exchanges in compliance with SEBI regulations.

16Dec 25

Biocon Announces $1.17 Billion BBL Acquisition, Maintains ICRA [AA] Rating

Biocon Limited has announced a major $1.17 billion acquisition to make Biocon Biologics Limited its wholly-owned subsidiary by acquiring minority stakes from Mylan Inc., Serum Institute Life Sciences, Tata Capital, and Activ Pine. The transaction will be funded through a combination of share swap worth $773 million and cash payment of $400 million, with funding structured through commercial paper and a ₹4,500 crore QIP. ICRA Limited has simultaneously reaffirmed Biocon's credit ratings at [AA] (Stable)/A1+ for ₹450 crore unallocated facilities, noting the strategic benefits of corporate structure simplification and expected operational synergies across the biopharmaceutical operations.

15Dec 25

Biocon Limited Launches GLP-1 Drug Liraglutide in Netherlands After MEB Approval

Biocon Limited has successfully launched its GLP-1 peptide Liraglutide in the Netherlands following approval from the Dutch Medicines Evaluation Board (MEB). The drug will be marketed under two registered brand names - Diavorin® for diabetes management and Vobexoryn® for obesity treatment - through distribution partner Pharmamedicb B.V. This represents Biocon's first European Union market entry under its own brand names, demonstrating the company's vertically integrated capabilities and commitment to expanding access to advanced metabolic treatments.

13Dec 25

Biocon Biologics Secures Global Settlement Agreement for YESAFILI Launch

Biocon Biologics has reached a settlement and license agreement with Regeneron and Bayer for worldwide commercialization of its biosimilar aflibercept, YESAFILI. The agreement allows for a UK launch in January 2026 and other countries in March 2026. YESAFILI, approved by EC and MHRA, treats various ophthalmology conditions. This expands Biocon's ophthalmology portfolio and global presence.

11Dec 25

S&P Global Places Biocon Biologics on Positive Credit Watch Following Accelerated Debt Reduction

S&P Global Ratings placed Biocon Biologics on positive credit watch on December 10, 2025, recognizing accelerated debt reduction progress. The company's BB long-term issuer credit rating and senior secured notes rating received positive outlook following Biocon's plan to make Biocon Biologics wholly owned through minority investor buyouts. S&P expects Biocon's adjusted debt to fall from ₹248 billion to ₹120 billion by March 2026, funded by ₹45 billion fresh equity issuance.

04Dec 25

Biocon to Explore Fundraising Options and Invest in Biocon Biologics

Biocon, a biopharmaceutical company, is considering raising funds through commercial paper or share issuance. Simultaneously, the company plans to invest in its subsidiary, Biocon Biologics, by purchasing securities from existing shareholders. Biocon's recent financial data shows growth in total assets (4.86%), current assets (7.29%), investments (12.73%), and total equity (9.64%) compared to the previous year.

02Dec 25

Biocon Announces December 2025 Launch for Denosumab Biosimilars in Europe and Worldwide

Biocon has announced the launch of its denosumab biosimilars, Vevzuo® and Evfaxy®, in European and global markets on December 2, 2025. The company has secured an agreement with Amgen for sales permission. These biosimilars, used for treating osteoporosis and preventing skeletal-related events in cancer patients, represent a significant expansion of Biocon's biosimilar portfolio and global market presence.

19Nov 25

Biocon Pharma Secures FDA Approval for Tofacitinib Extended-Release Tablets

Biocon Limited's subsidiary, Biocon Pharma Limited, has received FDA approval for Tofacitinib Extended-Release Tablets. The 11mg strength received final approval, while the 22mg strength got tentative approval. Tofacitinib, a JAK inhibitor, is used to treat chronic inflammatory conditions like rheumatoid arthritis and ulcerative colitis. This approval strengthens Biocon's complex drug products portfolio and expands its presence in the U.S. pharmaceutical market for chronic disease management.

18Nov 25

Biocon Reports Strong Q2 FY26 Results: 20% Revenue Growth Led by Biosimilars

Biocon Limited reported robust Q2 FY26 results with operating revenue up 20% YoY to INR 4,296 crores. Core EBITDA grew 23% to INR 1,218 crores, while EBITDA margin reached 21%. Biosimilars segment led growth with 25% revenue increase. The company reduced debt, launched new biosimilars, and expanded its generics and CRDMO businesses. Biocon expects continued margin improvement and growth across segments.

13Nov 25

SBI Mutual Fund Increases Stake in Biocon; Shares Hit 52-Week High Amid Merger Speculation

SBI Mutual Fund has acquired 370,150 shares of Biocon on November 11, 2025, increasing its stake from 4.97% to 5.00%. The fund now holds 66,865,887 shares in the biopharmaceutical company. This acquisition has triggered disclosure requirements due to crossing the 5% threshold. Biocon's total equity share capital consists of 1,336,963,635 equity shares with a face value of Rs. 5 each. The company recently held its Q2 FY26 Earnings Call on November 12, 2025.

11Nov 25

Biocon's Q2 Net Profit Soars to ₹1.3 Billion, Outperforming Estimates

Biocon reported a consolidated net profit of ₹1.30 billion for Q2 FY2024, a 379.7% increase from ₹0.27 billion in Q2 FY2023, exceeding analyst estimates of ₹0.75 billion. Revenue rose 19.6% to ₹42.95 billion, while EBITDA grew 21.9% to ₹8.35 billion. The company plans to acquire Compulsorily Convertible Debentures of Biocon Biologics for ₹3.00 billion, indicating strategic expansion in the biologics segment.

08Nov 25

Biocon's Visakhapatnam API Facility Receives Two Observations from US FDA Inspection

Biocon Limited's API facility in Visakhapatnam underwent a GMP surveillance inspection by the US FDA from November 3-7, 2025. The inspection resulted in two observations, which Biocon plans to address within the stipulated timeframe. The company stated that these observations are not expected to impact its business operations. Biocon has notified the BSE and NSE about the inspection outcome as part of its regulatory disclosure.

23Oct 25

Biocon Biologics Expands North American Presence with Health Canada Approval for Ustekinumab Biosimilar

Biocon Biologics Ltd (BBL) received approval from Health Canada for Yesintek™ and Yesintek™ I.V., biosimilars to Stelara® (ustekinumab). The products will be commercially available in mid-October 2025 for treating various conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This approval marks BBL's entry into the Canadian market, expanding its North American presence and immunology portfolio. The company plans to support patients through the My Biocon Biologics™ program and aims to improve biosimilar adoption in Canada's public and private markets.

21Oct 25

Biocon Chief Meets Karnataka Leadership, Pledges Support for Bengaluru Development

Kiran Mazumdar-Shaw, Biocon chief, met with Karnataka's top leadership, including CM Siddaramaiah and Deputy CM D K Shivakumar, to discuss Bengaluru's development. Mazumdar-Shaw assured cooperation for the city's progress. The government plans to meet with IT/BT industry leaders and visit local bodies near Greater Bengaluru. These meetings, which included interactions with opposition leaders, aim to address the city's infrastructure challenges collaboratively.

16Oct 25

Biocon Biologics Expands U.S. Insulin Market Reach Through Enhanced Civica Partnership

Biocon Biologics, a Biocon Ltd. subsidiary, has expanded its partnership with Civica to increase affordable insulin supply in the US. The multi-year agreement focuses on bringing a new Insulin Glargine medicine to the market. Biocon Biologics will manufacture and supply the product, while Civica will handle commercialization under its own label. The collaboration aims to address the needs of 38.4 million diabetes patients in the US. Biocon Biologics, ranked as the fourth largest insulin company globally, provides over 9.2 billion doses of insulin worldwide.

14Oct 25

Biocon Shares Worth Rs. 22.49 Crores Traded in NSE Block Deal

Biocon Ltd. experienced a significant block trade on the NSE, involving 642,850 shares at Rs. 349.80 per share, totaling Rs. 22.49 crores. The company recently submitted its regulatory compliance certificate under SEBI regulations, confirming timely completion of dematerialization requests and proper recording of securities.

11Oct 25

Biocon's New Jersey Facility Completes FDA Inspection with Single Observation

Biocon Limited's newly inaugurated manufacturing facility in Cranbury, New Jersey, underwent a Good Manufacturing Practice (GMP) inspection by the U.S. FDA. The inspection concluded with a single observation, which Biocon plans to address within the stipulated timeframe. The company does not anticipate any impact on its business operations. The Cranbury facility, inaugurated in September, is a key part of Biocon's U.S. expansion strategy, supporting capacity expansion and supply chain efficiency. Some products are already commissioned at the site, with additional launches planned. This facility aims to enable faster access to Biocon's vertically integrated portfolio, aligning with the company's mission to expand access to affordable therapies.

07Oct 25

Biocon's Subsidiary Secures USFDA Tentative Approval for Rifaximin Tablets

Biocon Pharma Limited, a subsidiary of Biocon Limited, in partnership with Carnegie Pharmaceuticals LLC, has received tentative approval from the U.S. FDA for their ANDA for Rifaximin Tablets (550 mg). Rifaximin is used to reduce hepatic encephalopathy recurrence risk and treat irritable bowel syndrome with diarrhea in adults. This approval is a significant step towards entering the U.S. market, though final approval and launch may be subject to additional requirements.

01Oct 25

Biocon Completes Early Redemption of Rs 1,070 Crore Non-Convertible Debentures

Biocon Limited has approved the early redemption of Non-Convertible Debentures (NCDs) worth Rs 1,070.00 crore. The Board of Directors made this decision on October 1, 2025, for 107,000 unlisted, secured, rated, redeemable NCDs originally issued on February 21, 2023. The company has completed the payment to debenture holders and the trustee, demonstrating its strong liquidity position. This move is expected to improve Biocon's debt profile and potentially reduce interest expenses.

01Oct 25

Biocon Biologics Secures U.S. Market Entry for Denosumab Biosimilars

Biocon Biologics Ltd. (BBL) has reached a settlement with Amgen Inc., allowing the launch of its denosumab biosimilars, Bosaya™ and Aukelso™, in the U.S. from October 1, 2025. The FDA approved both biosimilars in September 2025 with provisional interchangeability designation. Bosaya™ treats various forms of osteoporosis, while Aukelso™ is indicated for skeletal-related events in cancer patients. This move strengthens BBL's oncology portfolio and marks its entry into the bone health market, addressing significant health concerns affecting millions of Americans.

25Sept 25

Biocon Faces Rs. 2.02 Crore Tax Demand from Karnataka Commercial Tax Department

Biocon Limited has received a Show Cause Notice from Karnataka's Office of the Deputy Commissioner of Commercial Taxes, proposing a total demand of Rs. 2.02 crore for FY 2021-22. The demand includes Rs. 81.38 lakh in tax, Rs. 1.13 crore in interest, and Rs. 8.14 lakh in penalties. The notice outlines seven tax-related issues, including incorrect turnover reduction, short declaration of outward supplies, and input tax credit mismatches. Biocon states there is no material impact on its financials or operations and is taking appropriate actions to address the notice.

19Sept 25

Biocon Limited Fulfills Rs. 600 Crore Commercial Paper Buyback Obligation

Biocon Limited has successfully completed the buyback of Commercial Papers worth Rs. 600 crores on September 19, 2025. The CPs, originally issued on April 22, 2025, were used for refinancing existing borrowings. The company confirmed full compliance with regulatory requirements, maintaining standard asset classification for fund-based facilities, and reported no material changes in its financial status that could affect the CP's credit rating.

18Sept 25

Biocon Biologics' Yesafili Secures Funded Access in Ontario's Public Drug Program

Biocon Biologics' biosimilar drug Yesafili (aflibercept) has been included in Ontario's Public Drug Formulary. This inclusion provides funded access to the treatment for patients with retinal diseases in Canada's most populous province. Yesafili, used for conditions like age-related macular degeneration and diabetic macular edema, offers a more affordable alternative to the original biologic drug. This development expands access to treatment, potentially reducing costs for patients and the healthcare system. For Biocon Biologics, this represents a significant market opportunity in Canada and strengthens its position in the global biosimilars market.

17Sept 25

Biocon Sets Record Date for Rs. 600 Crore Commercial Paper Buyback

Biocon Limited announced September 18, 2025, as the record date for a Rs. 600 crore Commercial Paper buyback. Simultaneously, its subsidiary, Biocon Biologics Ltd., received FDA approval for two denosumab biosimilars: Bosaya™ and Aukelso™. These biosimilars, alternatives to Prolia® and Xgeva®, have been granted provisional interchangeability designation. The original products had nearly $5 billion in U.S. sales in 2024.

17Sept 25

Biocon Biologics Secures FDA Approval for Two Denosumab Biosimilars, Expanding Its Portfolio

Biocon Biologics Ltd. (BBL) has received FDA approval for Bosaya™ and Aukelso™, biosimilars of Prolia® and Xgeva® respectively. Bosaya™ is approved for treating various forms of osteoporosis, while Aukelso™ is indicated for preventing skeletal-related events in cancer patients and treating giant cell tumor of bone. Both biosimilars have provisional interchangeability designation. The approval could significantly impact the U.S. healthcare market, where denosumab generated nearly $5 billion in sales. The biosimilars demonstrated comparable quality, safety, and efficacy to their reference products in clinical trials.

15Sept 25

Biocon Sets Sights on Generic Ozempic Market, Targeting Emerging Markets by End-2026

Biocon, an Indian biopharmaceutical company, announces plans to enter the generic Ozempic market. The company aims to launch in emerging markets by end of 2026 and in the US by early 2026. Biocon already sells Liraglutide API in UK and Europe. The global GLP-1 market is estimated to exceed $160 billion by 2034, with Semaglutide patents expiring in 2031. Biocon has developed processes to compete with Chinese API sources and expects its Bengaluru plant to generate revenues within 2-3 years.

11Sept 25

Biocon Expands Global Footprint with First U.S. Manufacturing Facility in New Jersey

Biocon Limited has opened its first FDA-approved formulations facility in Cranbury, New Jersey, marking a significant expansion into U.S. manufacturing. The company invested over $30 million in the state-of-the-art plant, which has an annual production capacity of 2 billion tablets. The facility, operated by Biocon Generics Inc, has already begun commercializing products. The inauguration was attended by New Jersey Governor Phil Murphy and Biocon Chairperson Kiran Mazumdar-Shaw. This strategic move aims to enhance Biocon's supply chain resilience and accelerate its global footprint expansion in the U.S. healthcare market.

05Sept 25

Biocon Biologics Secures $30 Million Investment from Tata Capital Growth Fund

Biocon Limited announced that Tata Capital Growth Fund will invest Rs 225 crore for a 0.85% stake in its subsidiary, Biocon Biologics. The deal values Biocon Biologics at an equity valuation of Rs 26,250 crore and an enterprise valuation of Rs 30,400 crore. Biocon will retain a 95.25% stake in the biosimilars unit. The funds will be used for general corporate purposes, including loan repayment. Biocon Biologics aims to serve 5 million patients and achieve $1 billion in revenue by FY22. The transaction is subject to standard approvals. Separately, Biocon's management will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, in New York City.

04Sept 25

USFDA Inspection at Biocon Biologics Facility Results in Form 483 with Five Procedural Observations

Biocon Biologics' facility in Bengaluru underwent a routine FDA inspection, resulting in a Form 483 with five procedural observations. The company stated these don't involve data integrity issues or systemic non-compliance. Biocon plans to submit a comprehensive Corrective and Preventive Action plan within the FDA's timeline and doesn't anticipate any impact on commercial product supply. The inspection covered drug substance manufacturing units, analytical QC laboratories, microbiology laboratories, and warehouses.

26Aug 25

Biocon Pharma Secures Tentative FDA Approval for Generic Sitagliptin Tablets

Biocon Pharma, a subsidiary of Biocon Limited, has received tentative FDA approval for its Abbreviated New Drug Application (ANDA) of Sitagliptin tablets, used to treat Type 2 diabetes. The approval covers 25 mg, 50 mg, and 100 mg dosage strengths. This development strengthens Biocon's portfolio of vertically integrated drug products and positions the company to compete in the U.S. generic drug market for diabetes treatments.

15Aug 25

Biocon's Kiran Mazumdar-Shaw Advocates for Regulatory Reforms in Pharma Sector

Kiran Mazumdar-Shaw, Executive Chairperson of Biocon and Biocon Biologics, responded to PM Modi's Independence Day speech, emphasizing the need for self-reliance and innovation in the pharmaceutical sector. She stressed the importance of regulatory reforms to accelerate drug development, highlighting that the current lengthy process deters investment in innovative molecules. Mazumdar-Shaw advocated for developing homegrown solutions over relying on overseas products, citing China as an example of how regulatory ecosystems can drive domestic innovation. She expressed optimism about the government's intention to implement reforms, starting with changes in the GST system, which could create momentum for broader reforms in the pharmaceutical sector.

14Aug 25

Biocon Reports 15% Revenue Growth in Q1, Raises INR 4,500 Crores Through QIP

Biocon Limited reported a 15% year-on-year growth in operating revenue for Q1, reaching INR 3,942 crores. Core EBITDA increased by 11% to INR 1,003 crores. Biosimilars segment revenue grew 18%, while CRDMO and Generics segments saw 11% and 6% growth respectively. The company completed a INR 4,500 crore QIP, received regulatory approvals for biosimilars, and expanded facilities. Management expects strong double-digit growth for the full year.

08Aug 25

Biocon Shareholders Approve Re-appointment of Key Directors at 47th AGM

Biocon Limited held its 47th Annual General Meeting on August 8, 2025, approving significant board re-appointments. Shareholders re-elected Prof. Ravi Rasendra Mazumdar as a Director and Ms. Naina Lal Kidwai as an Independent Director for a five-year term. The company reported strong financial performance with consolidated revenue of ₹3,942.00 crore, up 15% year-on-year. Executive Chairperson Kiran Mazumdar-Shaw highlighted strategic initiatives including capital investments, manufacturing capacity expansion, and R&D enhancement. Biocon's focus remains on accelerating global reach for essential medicines and driving sustainable growth.

08Aug 25

Biocon Reports Strong Q1 FY26 Growth: Revenue Up 15%, Biosimilars Lead Gains

Biocon Limited announced robust Q1 FY26 results with consolidated revenue reaching Rs 3,942.00 crore, up 15% year-on-year. EBITDA grew 19% to Rs 829.00 crore. Biosimilars segment led growth with 18% revenue increase. The company received FDA approval for Kirsty™, launched Yesafili™ in Canada, and raised Rs 4,500.00 crore through QIP. Management expressed confidence in continued growth across all segments.

04Aug 25

Biocon Shares Worth Rs. 60.87 Crores Traded in NSE Block Deal

Biocon Ltd. experienced a significant block trade on the NSE, involving 1,623,691 shares at Rs. 374.90 per share. The total transaction value amounted to Rs. 60.87 crores. This large-scale trade demonstrates substantial investor interest in the biopharmaceutical company's stock and could potentially impact short-term price movements.

23Jul 25

Biocon Biologics Expands Global Footprint with Nepexto Launch in Australia

Biocon Biologics, a subsidiary of Biocon Limited, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in the Australian market. This launch marks the company's entry into Australia's biosimilar landscape, offering a more affordable alternative for treating autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The move is expected to open new avenues for growth, enhance Biocon's global presence, and potentially contribute to revenue growth.

17Jul 25

Biocon Ltd. Sees Block Trade of 788,078 Shares Worth Rs. 31 Crores

A significant block trade of Biocon Ltd. shares occurred on the National Stock Exchange. Approximately 788,078 shares, valued at Rs. 31.00 crores, were traded at Rs. 393.30 per share. The transaction, involving a large volume of privately negotiated securities, could indicate shifts in institutional holdings or significant shareholder movements.

16Jul 25

Biocon's Kirsty™ Secures FDA Approval as First Interchangeable Rapid-Acting Insulin Aspart in US

Biocon Ltd's subsidiary, Biocon Biologics Ltd, has received FDA approval for Kirsty™ (Insulin Aspart-xjhz), the first interchangeable biosimilar to NovoLog® in the US. Kirsty™, a rapid-acting human insulin analog for diabetes treatment, will be available in prefilled pens and multiple-dose vials. The approval expands Biocon's biosimilar insulin portfolio, which includes Semglee®. With 38.4 million diabetics in the US, this approval aims to improve insulin accessibility and affordability. Analysts project annual sales of $80-100 million post-formulary addition for Kirsty™.

16Jul 25

Biocon Biologics Secures FDA Approval for Kirsty™, First Interchangeable Rapid-Acting Insulin Aspart in U.S.

Biocon Biologics, a Biocon Ltd subsidiary, has received FDA approval for Kirsty™ (Insulin Aspart-xjhz), the first interchangeable biosimilar to NovoLog® in the US. Kirsty™ is a rapid-acting insulin for diabetes management in adults and children, available in prefilled pens and vials. This approval expands Biocon's biosimilar insulin portfolio in the US market, where 38.40 million people have diabetes. The US Insulin Aspart market is valued at approximately $1.90 billion. Biocon Biologics, a global leader in biosimilars and insulin, serves over 5.80 million patients annually with 9.20 billion insulin doses globally.

07Jul 25

Biocon Biologics Secures UK Approval for Two Denosumab Biosimilars

Biocon Biologics, a Biocon Limited subsidiary, has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for two denosumab biosimilars, Vevzuo and Evfaxy. These biosimilars, designed to treat bone-related conditions, mark a significant milestone in the company's international expansion. The approval is expected to enhance Biocon Biologics' portfolio in the UK market, potentially increase accessibility to bone health treatments, and strengthen its position in the global biosimilars market.

03Jul 25

Biocon Biologics Secures European Commission Approval for Two Denosumab Biosimilars

Biocon Biologics, a subsidiary of Biocon Limited, has received European Commission approval for two denosumab biosimilars, Vevzuo and Evfraxy. Vevzuo is approved for preventing skeletal-related events in adults with advanced bone malignancies, while Evfraxy is authorized for treating osteoporosis and bone loss associated with long-term glucocorticoid therapy. This approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and is expected to strengthen Biocon Biologics' position in the global biosimilars market.

02Jul 25

Biocon Sets Sights on Generic Versions of Popular Weight Loss Drugs

Biocon, an Indian biopharmaceutical company, announces plans to seek approval for generic versions of diabetes and weight loss drugs Ozempic and Wegovy. The company aims to enter the market as these drugs' patents expire next year. This move could potentially increase accessibility to these treatments through lower-cost alternatives and intensify market competition in the diabetes and weight loss medication sector.

30Jun 25

Biocon Biologics Boosts Insulin Supply in Malaysia, Treating Over 345,000 Patients

Biocon Biologics, a subsidiary of Biocon Ltd, has significantly increased its insulin supply to the Malaysian Health Ministry, providing over 100 million cartridges of recombinant human insulin. This expansion has enabled the treatment of more than 345,000 patients in Malaysia, showcasing the company's ability to meet substantial healthcare demands and strengthening its position in the Malaysian market.

27Jun 25

Biocon Biologics Secures Health Canada Approval for Yesafili, Eyes Global Launch

Biocon Biologics, a Biocon Limited subsidiary, has received Health Canada approval for Yesafili, its biosimilar version of Aflibercept. This approval is part of the company's global expansion strategy, with plans to launch the product worldwide starting July 2025. Yesafili is used to treat eye conditions such as age-related macular degeneration and diabetic macular edema.

26Jun 25

Biocon Invests $198.5 Million in Biocon Biologics Through Debenture Acquisition

Biocon has acquired 1,125 Optionally Convertible Debentures (OCDs) of its subsidiary, Biocon Biologics, for $198.50 million. This internal financial transaction could be aimed at strengthening the subsidiary's financial position, providing capital for expansion, or potentially increasing Biocon's stake in Biocon Biologics in the future. The move demonstrates Biocon's commitment to its biologics business and may signal confidence in Biocon Biologics' long-term prospects.

24Jun 25

Biocon Biologics Launches Patient Support Program in Malaysia for Cancer Treatment

Biocon Biologics, a subsidiary of Biocon, has partnered with the National Cancer Society of Malaysia to launch a patient support program. The initiative aims to enhance the affordability and accessibility of biosimilar medications for cancer patients in Malaysia. This strategic collaboration focuses on reducing the financial burden of cancer treatment and improving access to advanced biosimilar therapies. The program could potentially lead to expanded treatment options, improved patient outcomes, and economic relief for cancer patients.

24Jun 25

Biocon Raises Rs 4,500 Crore Through QIP, Set to Increase Stake in Biocon Biologics

Biocon Ltd has raised Rs 4,500 crore through a Qualified Institutional Placement (QIP) to repay private equity investors involved in the Viatris biosimilars business acquisition. This will increase Biocon's stake in Biocon Biologics from 72% to 79%. The company's bank and bond debt remains at $1.20 billion. Biocon's total assets grew by 7.74% to Rs 56,070.70 crore, while total equity increased by 12.39% to Rs 25,274.80 crore. Current assets rose by 23.07%, and current liabilities increased by 80.46%. The company's capital work-in-progress stands at Rs 7,993.30 crore, up 9.24% year-over-year.

23Jun 25

Biocon Explores Merger of Biocon Biologics into Parent Company

Biocon is exploring the possibility of merging its subsidiary, Biocon Biologics, back into its main operations. This potential corporate restructuring could streamline operations, enhance efficiency, and align with long-term strategic goals. The move might lead to synergies across various business segments. However, no official announcements or specific details have been made public yet.

20Jun 25

Biocon Secures ₹4,500 Crore in Landmark Equity Fundraising

Biocon, a leading biopharmaceutical company, has successfully raised ₹4,500 crore through an equity fundraising event. This marks the company's first major fundraising initiative since its initial public offering in 2004. The substantial amount raised indicates strong investor confidence in Biocon's potential. While the specific use of funds is not disclosed, the capital could potentially be allocated towards research and development, expansion, strategic acquisitions, or debt reduction.

20Jun 25

Biocon Completes First Equity Fundraising Since 2004, Raises Rs 4,500 Crore Through QIP

Biocon Ltd has completed a Qualified Institutional Placement (QIP), raising Rs 4,500 crore by issuing 136,363,635 equity shares at Rs 330.00 per share. The funds will be used to purchase outstanding debentures from a subsidiary, repay existing borrowings, and for general corporate purposes. This marks Biocon's first equity fundraising since 2004, demonstrating its ability to attract significant capital from institutional investors.

19Jun 25

Biocon Raises ₹4,500 Crore Through Successful Qualified Institutions Placement

Biocon has completed a Qualified Institutions Placement (QIP), raising ₹4,500 crore by issuing 13.63 crore shares at ₹330 per share, a 3% discount to the floor price. The funds will be used to reduce debt and strengthen the company's balance sheet. This successful capital raise demonstrates investor confidence and provides Biocon with increased financial flexibility for future strategic initiatives.

17Jun 25

Biocon Launches Rs 4,500 Crore QIP to Provide Investor Exits and Close Listing Window for Subsidiary

Biocon has initiated a Qualified Institutions Placement (QIP) to raise Rs 4,500 crore, setting a floor price of Rs 340.20 per equity share. The funds will be used to provide exits to private equity investors in Biocon Biologics Ltd, redeem Optionally Convertible Debentures issued to Goldman Sachs entities, and pre-pay other financial commitments. This move will increase Biocon's stake in Biocon Biologics to 73.84%. The final issue price will be determined in consultation with Book Running Lead Managers.

16Jun 25

Biocon Approves Qualified Institutional Placement at ₹340.20 Per Share

Biocon, a leading biopharmaceutical company, has approved a Qualified Institutional Placement (QIP) at ₹340.20 per share. This move allows the company to raise capital from qualified institutional buyers without pre-issue filings to market regulators. The QIP approval indicates potential institutional investor confidence and may impact Biocon's short-term stock trading.

16Jun 25

Biocon Launches ₹4,500 Crore QIP with ₹340.20/Share Floor Price

Biocon has initiated a Qualified Institutional Placement (QIP) to raise ₹4,500 crore, setting a floor price of ₹340.20 per share with a potential 5% discount. The funds will be used to purchase debentures from its subsidiary, Biocon Biologics, and manage existing financial commitments. Kotak Mahindra Capital, Goldman Sachs, and BofA Securities are likely advisors for the capital raise, which was approved by the board in April and is expected to close within 3-4 months.

03Jun 25

Biocon Secures DCGI Approval for Generic Diabetes Drug Liraglutide

Biocon Ltd and its subsidiary Biocon Pharma have received approval from the Drugs Controller General of India (DCGI) for Liraglutide, a generic version of the diabetes medication Victoza. The company is preparing for a swift market launch across India through its commercialization partners. This approval aims to address the needs of Type 2 Diabetes Mellitus patients in India by potentially making the treatment more accessible and affordable.

02Jun 25

Biocon Secures Approval for Generic Liraglutide in India, Expanding Diabetes Treatment Options

Biocon has obtained regulatory approval to market a generic version of Liraglutide, a type 2 diabetes medication, in India. This approval allows Biocon to expand its diabetes treatment portfolio and potentially increase access to affordable diabetes care in the country. Liraglutide, a GLP-1 receptor agonist, is used to improve blood sugar control in adult patients with type 2 diabetes. The introduction of this generic version aligns with Biocon's mission to provide high-quality, affordable medications for chronic conditions and strengthens its position in the diabetes care segment.

15May 25

Biocon Pharma Secures FDA Approval for Generic Rivaroxaban Tablets

Biocon Ltd.'s subsidiary, Biocon Pharma, has received FDA approval for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP. The approval covers four strengths: 2.5 mg, 10 mg, 15 mg, and 20 mg. This generic version of the anticoagulant medication positions Biocon to compete in the U.S. anticoagulant market, potentially increasing access to affordable treatments for blood clot prevention and treatment.

12May 25

Biocon Shares Dip Despite Analyst Optimism; Q4 Results Show Mixed Performance

Biocon Ltd experienced a share price decline on May 12, despite 'buy' ratings from Jefferies and Citi with price targets of ₹370 and ₹430 respectively. Q4 FY2025 results showed mixed performance: revenue grew 15.41% to ₹4,415.40 crore, EBITDA increased 42.35% to ₹1,076.60 crore, and net profit surged 466.46% to ₹459.40 crore. However, ex-gRevlimid EBITDA margin declined. The company plans an equity fund raise and aims to launch five new biosimilar assets in 12-18 months. US drug pricing policy changes could impact future performance.